News

J&J's ICOTYDE meets Phase 3 psoriatic arthritis endpoint in biologic-naive patients

What's the update? On 7 November 2026, Johnson & Johnson Innovative Medicine announced that ICOTYDE (icotrokinra), its once-daily oral peptide blocking the IL-23 receptor, met the primary endpoint in the Phase 3 ICONIC-PsA1 trial in psoriatic arthritis. The results were presented as a late-breaking poster at the American College of Rheumatology's annual meeting.

The results: In biologic-naive adults with active psoriatic arthritis, 58% of patients receiving ICOTYDE 200 mg achieved an ACR20 response at week 16 — a measure of at least a 20% improvement in joint symptoms — versus 41% on placebo. Numerically higher proportions also achieved the deeper ACR50 (29% vs 16%) and ACR70 (13% vs 5%) responses. Safety findings were consistent with ICOTYDE's established profile, with no new safety signals.

Why it matters: Psoriatic arthritis combines joint inflammation with psoriasis, and most patients are treated with injected biologics. These are the first Phase 3 results showing ICOTYDE, a pill, improving joint disease activity in this population, expanding the drug's potential beyond plaque psoriasis where it recently reported positive head-to-head Phase 3 data. ICOTYDE was jointly discovered with Protagonist Therapeutics, with J&J holding worldwide rights from Phase 2 onwards.

Read more: Johnson & Johnson via PR Newswire, 07 November 2026

More top stories